Study: ENGOT-en30 / DESTINY Endometrial-02

A Phase 3, Multicenter, Randomized, Open label Trial of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy as Adjuvant Treatment for HER2-Expressing (IHC 3+/IHC2+) Endometrial Cancer

MaNGO Sites list

Prov.	City	Site	Principal Investigator	Active
BS	Brescia	Spedali Civili	Germana Tognon	Yes
FI	Firenze	Ospedale Careggi	Maria Cristina Petrella	Yes
LC	Lecco	Ospedale Manzoni	Alessandra Crippa	Yes
MB	Monza	Ospedale San Gerardo	Stefania Canova	Yes
MI	Milano	Istituto Europeo di Oncologia	**Nicoletta Colombo ***	Yes
MI	Milano	Istituto Nazionale dei Tumori	Francesco Raspagliesi	Yes
PD	Padova	Istituto Oncologico Veneto	Valentina Guarneri	Yes
RE	Reggio Emilia	Arcispedale S. Maria Nuova	Alessandra Bologna	Yes
TO	Torino	Ospedale Mauriziano	Annamaria Ferrero	Yes

*** MaNGO Principal Investigator**